Monopar Therapeutics (NASDAQ:MNPR) Shares Up 10.2%

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) shot up 10.2% during trading on Friday . The stock traded as high as $0.76 and last traded at $0.73. 129,520 shares were traded during mid-day trading, a decline of 97% from the average session volume of 3,984,959 shares. The stock had previously closed at $0.66.

Wall Street Analysts Forecast Growth

Separately, Jonestrading raised shares of Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Thursday, April 11th.

Monopar Therapeutics Stock Performance

The company has a market cap of $12.69 million, a price-to-earnings ratio of -1.19 and a beta of 1.17. The stock’s fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $0.52.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, March 28th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. Analysts predict that Monopar Therapeutics Inc. will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

An institutional investor recently bought a new position in Monopar Therapeutics stock. Windsor Advisory Group LLC purchased a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 89,974 shares of the company’s stock, valued at approximately $56,000. Windsor Advisory Group LLC owned approximately 0.64% of Monopar Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.